Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

Deals > All

Total search results: 9813 | Ordered by Date (descending)
next pagenext page 1 2 3 4 ... 97 98 99  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Murdoch Univ–Bruker Corp: mass spectrometer, 2018 supply ordered impact-II UHR-QTOF LC-MS/MS system 2018-12-31
Murdoch Univ–Bruker Corp: mass spectrometer, 2018 supply ordered timsTOF Pro LC/CCS/MS/MS system 2018-12-31
Murdoch Univ–Bruker Corp: NMR spectrometer, 2018 supply ordered Avance IVDr 600 NMR system 2018-12-31
Procarta Biosystems–Novo Group: investment, 2018 investment €1.5m by Novo REPAIR Impact Fund 2018-12-31
Harpoon Therapeutics–SEVERAL: investment, 201812– IPO $86m FILED 2018-12-27
Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS 2018-12-24
Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners 2018-12-24
Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation 2018-12-24
Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management 2018-12-24
Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health 2018-12-24
Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital 2018-12-24
Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech 2018-12-24
Nabriva–Hercules Technology: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital 2018-12-21
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Morphogen-IX–Cambridge Innovation Capital: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor CIC 2018-12-20
Morphogen-IX–Medicxi Ventures: investment, 201812 financing round Series B totalling £18.4m incl existing + lead investor Medicxi 2018-12-20
Morphogen-IX–SEVERAL: investment, 201812 financing round Series B £18.4m ($23.2m) led by Medicxi + incl CIC + Cambridge Enterprise 2018-12-20
Morphogen-IX–Univ Cambridge: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor Cambridge Enterprise 2018-12-20
Altheia Science–SEVERAL: investment, 201812 financing round Series A final closing €7.7m ($8.3m) bringing total round to €17m ($19.3m) 2018-12-19
Annexon Biosciences–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Annexon Biosciences–SEVERAL: investment, 201812 financing round Series C $75m led by new investor Bain Capital Life Sciences 2018-12-19
Cellestia Biotech–PPF Group: investment, 201812 financing round Series A totalling CHF20m incl existing + co-lead investor Sotio/PPF Group 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb 2018-12-18
PreOmics–High-Tech Gründerfonds: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–Think.Health Ventures: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
Carmat–EU (govt): credit, 201812– EFSI €30m loan from EIB to move artificial heart towards marketing 2018-12-17
Seer–Invus Group: investment, –201812 financing rounds Series A + B totalling $36m incl Series B lead investor Invus 2018-12-17
Seer–Maverick Ventures: investment, –201812 financing rounds Series A + B totalling $36m incl Series A lead investor Maverick Ventures 2018-12-17
Seer–SEVERAL: investment, –201812 financing rounds Series A + B of $36m until 12/18 as company emerges from stealth 2018-12-17
Kurma–France (govt): investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–Idinvest Partners: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–NewCap: public relations, 201812 service existent by NewCap 2018-12-14
Kurma–Servier: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–SEVERAL: investment, 201812 first closing of Kurma Biofund III with target for final closing of €150m 2018-12-14
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Pharvaris–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
Step Pharma–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
Mestrelab Research–Bruker Corp: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership 2018-12-13
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
JnJ–BiomX: biomarker discovery, 201812– collab using XMarker microbiome-based marker discovery platform for IBD therapeutics PDx 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
Synthace–SEVERAL: investment, 201812 financing round Series B $25.6m led by Horizons Ventures 2018-12-12
DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
AstraZeneca–Cancer Research UK: functional genomics, 201812– collab establishment of joint venture Functional Genomics Centre in Cambridge 2018-12-10
Chiesi–Centogene: genetic services, 201812– collab epidemiology study in lysosomal storage diseases with focus on AM by Centogene for Chiesi GmbH 2018-12-10
Genomics plc–F-Prime: investment, 201812 financing round Series B 2nd closing totalling £8m from Foresite Capital + F-Prime Capital 2018-12-10
Genomics plc–Foresite Capital: investment, 201812 financing round Series B 2nd closing totalling £8m from Foresite Capital + F-Prime Capital 2018-12-10
Genomics plc–SEVERAL: investment, 201812 financing round Series B 2nd closing £8m from Foresite Capital + F-Prime Capital bringing total round to £33m 2018-12-10
genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models 2018-12-10
Lonza–General Electric: biologics manufacuturing technology, 201812–2020 supply biologics facility in Guangzhou using KUBio platform by GE Healthcare 2018-12-10
Spatial Transcriptomics–10x Genomics: investment, 201812 acquisition of Spatial by 10x Genomics 2018-12-10
Alacris–Seedmatch: financial services, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Alacris–SEVERAL: investment, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB 2018-12-06
Merck (DE)–Cyclica: drug discovery services, 201812– collab using cloud-based proteome screening platform for small molecule drug development 2018-12-06
Novartis–Qiagen: molecular companion diagnostics, 201812– collab devlepm of CDx for alpelisib (BYL719) 2018-12-06
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
Apogenix–Hopp Group: investment, 201812 existent investment dievini Hopp owns 92% of Apogenix AG 2018-12-05
Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA 2018-12-05
Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA 2018-12-05
CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG 2018-12-05
Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG 2018-12-05
Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH 2018-12-05
Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH 2018-12-05
Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH 2018-12-05
Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH 2018-12-05
Sillages Paris–L’Oréal: investment, 201812 acquisition of minority share by BOLD fund as inaugural investment of BOLD 2018-12-05
Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est 2018-12-04
Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF 2018-12-04
Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est 2018-12-04
Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs 2018-12-04
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
Argen-X–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argen-X: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
Tesaro–GSK: investment, 201812–201901 acquisition $5.1b (£4b) in cash incl net debt assumption of Tesaro Inc by GSK 2018-12-03
Aprea–SEVERAL: investment, 201812 financing round Series C €50m led by new investor Redmile Group 2018-12-02
Igem Therapeutics–SEVERAL: investment, 201811 financing round Series £3m final closing bringing total round to £5m 2018-11-30
Autolus–AbCellera: drug target discovery, 201811– collab discovery of antibodies for targeted CAR-T cell therapies 2018-11-29
Hookipa–DarwinHealth: personalised medicine, 201811– collab research + license agreem to develop I-O treatments using systems biology 2018-11-28
ABP (NL)–Optimum Strategic Communications: public relations, 201811 service existent by Optimum for Inkef Capital 2018-11-27
Engitix–Instinctif Partners: public relations, 201811 service existent by Instinctif 2018-11-27
Engitix–SEVERAL: investment, 201811 financing round Series A £5m led by private investor 2018-11-27
Genomics Medicine Ireland–Wuxi PharmaTech: investment, 201811 acquisition of Ireland Medicine Ireland by WuXi NextCode 2018-11-27
Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures 2018-11-27
SpinDiag–SEVERAL: investment, 201811 financing round Series A €3m 2018-11-27
X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED 2018-11-27
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Adrenomed–MC Services: public relations, 201811 service existent by MC Services 2018-11-26
Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors 2018-11-26
Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners 2018-11-26
Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development 2018-11-26
Fluidic Analytics–Amadeus Capital: investment, 201811 financing round totalling $31m incl existing + co-investor Amadeus Capital Partners 2018-11-26
next pagenext page 1 2 3 4 ... 97 98 99  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top